{"id":7601,"date":"2024-07-23T10:24:37","date_gmt":"2024-07-23T09:24:37","guid":{"rendered":"https:\/\/els-solutions.com\/cms\/dev\/?p=7601"},"modified":"2024-07-23T10:24:37","modified_gmt":"2024-07-23T09:24:37","slug":"nasal-medication-anaphylactic-reactions","status":"publish","type":"post","link":"https:\/\/els-solutions.com\/en\/nasal-medication-anaphylactic-reactions\/","title":{"rendered":"First nasal medication to treat anaphylactic reactions"},"content":{"rendered":"<\/p>\n

First nasal medicine to treat anaphylactic reactions<\/strong><\/p>\n

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has approved Eurneffy (epinephrine) for use in the European Union. This medicine is the first to be administered through the nose to treat anaphylactic reaction emergencies and offers new hope for those suffering from severe allergies. Read more here<\/span><\/a><\/p>\n

If you need more information about regulatory services, ELS can certainly help.<\/p>\n

Please do not hesitate to c<\/span>ontact your local ELS consultant<\/a>\u00a0or via email info@elssolutions.pt<\/p>\n

\n","protected":false},"excerpt":{"rendered":"

The EMA approves Eurneffy, the first nasal medicine for anaphylactic emergencies, through the Committee for Medicinal Products for Human Use.<\/p>\n","protected":false},"author":9,"featured_media":7591,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[54,61],"tags":[62],"class_list":["post-7601","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general","category-news","tag-news"],"yoast_head":"\nFirst nasal medication to combat anaphylactic reactions<\/title>\n<meta name=\"description\" content=\"The EMA approves Eurneffy, the first nasal medicine for anaphylactic emergencies, through the Committee for Medicinal Products for Human Use.\" \/>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"First nasal medication to combat anaphylactic reactions\" \/>\n<meta property=\"og:description\" content=\"The EMA approves Eurneffy, the first nasal medicine for anaphylactic emergencies, through the Committee for Medicinal Products for Human Use.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/els-solutions.com\/en\/nasal-medication-anaphylactic-reactions\/\" \/>\n<meta property=\"og:site_name\" content=\"ELS Group - Accelerating Innovation\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/els.solutions\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-07-23T09:24:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/els-solutions.com\/cms\/wp-content\/uploads\/2024\/07\/ELS-Solutions-First-drug-for-nasal-administration-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Marketing ELS\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Marketing ELS\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/els-solutions.com\/en\/nasal-medication-anaphylactic-reactions\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/els-solutions.com\/en\/nasal-medication-anaphylactic-reactions\/\"},\"author\":{\"name\":\"Marketing ELS\",\"@id\":\"https:\/\/els-solutions.com\/en\/#\/schema\/person\/9fb8dae537039679cfc537a000df6ca3\"},\"headline\":\"First nasal medication to treat anaphylactic reactions\",\"datePublished\":\"2024-07-23T09:24:37+00:00\",\"dateModified\":\"2024-07-23T09:24:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/els-solutions.com\/en\/nasal-medication-anaphylactic-reactions\/\"},\"wordCount\":819,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/els-solutions.com\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/els-solutions.com\/en\/nasal-medication-anaphylactic-reactions\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/els-solutions.com\/cms\/wp-content\/uploads\/2024\/07\/ELS-Solutions-First-drug-for-nasal-administration-1.jpg\",\"keywords\":[\"News\"],\"articleSection\":[\"General\",\"News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/els-solutions.com\/en\/nasal-medication-anaphylactic-reactions\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/els-solutions.com\/en\/nasal-medication-anaphylactic-reactions\/\",\"url\":\"https:\/\/els-solutions.com\/en\/nasal-medication-anaphylactic-reactions\/\",\"name\":\"First nasal medication to combat anaphylactic reactions\",\"isPartOf\":{\"@id\":\"https:\/\/els-solutions.com\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/els-solutions.com\/en\/nasal-medication-anaphylactic-reactions\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/els-solutions.com\/en\/nasal-medication-anaphylactic-reactions\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/els-solutions.com\/cms\/wp-content\/uploads\/2024\/07\/ELS-Solutions-First-drug-for-nasal-administration-1.jpg\",\"datePublished\":\"2024-07-23T09:24:37+00:00\",\"dateModified\":\"2024-07-23T09:24:37+00:00\",\"description\":\"The EMA approves Eurneffy, the first nasal medicine for anaphylactic emergencies, through the Committee for Medicinal Products for Human Use.\",\"breadcrumb\":{\"@id\":\"https:\/\/els-solutions.com\/en\/nasal-medication-anaphylactic-reactions\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/els-solutions.com\/en\/nasal-medication-anaphylactic-reactions\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/els-solutions.com\/en\/nasal-medication-anaphylactic-reactions\/#primaryimage\",\"url\":\"https:\/\/els-solutions.com\/cms\/wp-content\/uploads\/2024\/07\/ELS-Solutions-First-drug-for-nasal-administration-1.jpg\",\"contentUrl\":\"https:\/\/els-solutions.com\/cms\/wp-content\/uploads\/2024\/07\/ELS-Solutions-First-drug-for-nasal-administration-1.jpg\",\"width\":1200,\"height\":600,\"caption\":\"Medicamento nasal para emerg\u00eancias anafil\u00e1ticas\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/els-solutions.com\/en\/nasal-medication-anaphylactic-reactions\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\/\/els-solutions.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"First nasal medication to treat anaphylactic reactions\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/els-solutions.com\/en\/#website\",\"url\":\"https:\/\/els-solutions.com\/en\/\",\"name\":\"ELS Group - Accelerating Innovation\",\"description\":\"Assessoria estrat\u00e9gia para a Ind\u00fastria Farmac\u00eautica\",\"publisher\":{\"@id\":\"https:\/\/els-solutions.com\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/els-solutions.com\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/els-solutions.com\/en\/#organization\",\"name\":\"ELS Group - Accelerating Innovation\",\"url\":\"https:\/\/els-solutions.com\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/els-solutions.com\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/els-solutions.com\/cms\/wp-content\/uploads\/2023\/08\/ELS-NewLogo-ColorBlack-1-e1691153715735.png\",\"contentUrl\":\"https:\/\/els-solutions.com\/cms\/wp-content\/uploads\/2023\/08\/ELS-NewLogo-ColorBlack-1-e1691153715735.png\",\"width\":2226,\"height\":1080,\"caption\":\"ELS Group - Accelerating Innovation\"},\"image\":{\"@id\":\"https:\/\/els-solutions.com\/en\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/els.solutions\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/els-solutions.com\/en\/#\/schema\/person\/9fb8dae537039679cfc537a000df6ca3\",\"name\":\"Marketing ELS\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/els-solutions.com\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/b785df1d10c9806cc43fcea2dbf585b96a8761ff697010979d603fc5b7a9ca7b?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/b785df1d10c9806cc43fcea2dbf585b96a8761ff697010979d603fc5b7a9ca7b?s=96&d=mm&r=g\",\"caption\":\"Marketing ELS\"},\"sameAs\":[\"https:\/\/els-solutions.com\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"First nasal medication to combat anaphylactic reactions","description":"The EMA approves Eurneffy, the first nasal medicine for anaphylactic emergencies, through the Committee for Medicinal Products for Human Use.","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"First nasal medication to combat anaphylactic reactions","og_description":"The EMA approves Eurneffy, the first nasal medicine for anaphylactic emergencies, through the Committee for Medicinal Products for Human Use.","og_url":"https:\/\/els-solutions.com\/en\/nasal-medication-anaphylactic-reactions\/","og_site_name":"ELS Group - Accelerating Innovation","article_publisher":"https:\/\/www.facebook.com\/els.solutions\/","article_published_time":"2024-07-23T09:24:37+00:00","og_image":[{"width":1200,"height":600,"url":"https:\/\/els-solutions.com\/cms\/wp-content\/uploads\/2024\/07\/ELS-Solutions-First-drug-for-nasal-administration-1.jpg","type":"image\/jpeg"}],"author":"Marketing ELS","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Marketing ELS","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/els-solutions.com\/en\/nasal-medication-anaphylactic-reactions\/#article","isPartOf":{"@id":"https:\/\/els-solutions.com\/en\/nasal-medication-anaphylactic-reactions\/"},"author":{"name":"Marketing ELS","@id":"https:\/\/els-solutions.com\/en\/#\/schema\/person\/9fb8dae537039679cfc537a000df6ca3"},"headline":"First nasal medication to treat anaphylactic reactions","datePublished":"2024-07-23T09:24:37+00:00","dateModified":"2024-07-23T09:24:37+00:00","mainEntityOfPage":{"@id":"https:\/\/els-solutions.com\/en\/nasal-medication-anaphylactic-reactions\/"},"wordCount":819,"commentCount":0,"publisher":{"@id":"https:\/\/els-solutions.com\/en\/#organization"},"image":{"@id":"https:\/\/els-solutions.com\/en\/nasal-medication-anaphylactic-reactions\/#primaryimage"},"thumbnailUrl":"https:\/\/els-solutions.com\/cms\/wp-content\/uploads\/2024\/07\/ELS-Solutions-First-drug-for-nasal-administration-1.jpg","keywords":["News"],"articleSection":["General","News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/els-solutions.com\/en\/nasal-medication-anaphylactic-reactions\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/els-solutions.com\/en\/nasal-medication-anaphylactic-reactions\/","url":"https:\/\/els-solutions.com\/en\/nasal-medication-anaphylactic-reactions\/","name":"First nasal medication to combat anaphylactic reactions","isPartOf":{"@id":"https:\/\/els-solutions.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/els-solutions.com\/en\/nasal-medication-anaphylactic-reactions\/#primaryimage"},"image":{"@id":"https:\/\/els-solutions.com\/en\/nasal-medication-anaphylactic-reactions\/#primaryimage"},"thumbnailUrl":"https:\/\/els-solutions.com\/cms\/wp-content\/uploads\/2024\/07\/ELS-Solutions-First-drug-for-nasal-administration-1.jpg","datePublished":"2024-07-23T09:24:37+00:00","dateModified":"2024-07-23T09:24:37+00:00","description":"The EMA approves Eurneffy, the first nasal medicine for anaphylactic emergencies, through the Committee for Medicinal Products for Human Use.","breadcrumb":{"@id":"https:\/\/els-solutions.com\/en\/nasal-medication-anaphylactic-reactions\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/els-solutions.com\/en\/nasal-medication-anaphylactic-reactions\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/els-solutions.com\/en\/nasal-medication-anaphylactic-reactions\/#primaryimage","url":"https:\/\/els-solutions.com\/cms\/wp-content\/uploads\/2024\/07\/ELS-Solutions-First-drug-for-nasal-administration-1.jpg","contentUrl":"https:\/\/els-solutions.com\/cms\/wp-content\/uploads\/2024\/07\/ELS-Solutions-First-drug-for-nasal-administration-1.jpg","width":1200,"height":600,"caption":"Medicamento nasal para emerg\u00eancias anafil\u00e1ticas"},{"@type":"BreadcrumbList","@id":"https:\/\/els-solutions.com\/en\/nasal-medication-anaphylactic-reactions\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/els-solutions.com\/en\/"},{"@type":"ListItem","position":2,"name":"First nasal medication to treat anaphylactic reactions"}]},{"@type":"WebSite","@id":"https:\/\/els-solutions.com\/en\/#website","url":"https:\/\/els-solutions.com\/en\/","name":"ELS Group - Accelerating Innovation","description":"Assessoria estrat\u00e9gia para a Ind\u00fastria Farmac\u00eautica","publisher":{"@id":"https:\/\/els-solutions.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/els-solutions.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/els-solutions.com\/en\/#organization","name":"ELS Group - Accelerating Innovation","url":"https:\/\/els-solutions.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/els-solutions.com\/en\/#\/schema\/logo\/image\/","url":"https:\/\/els-solutions.com\/cms\/wp-content\/uploads\/2023\/08\/ELS-NewLogo-ColorBlack-1-e1691153715735.png","contentUrl":"https:\/\/els-solutions.com\/cms\/wp-content\/uploads\/2023\/08\/ELS-NewLogo-ColorBlack-1-e1691153715735.png","width":2226,"height":1080,"caption":"ELS Group - Accelerating Innovation"},"image":{"@id":"https:\/\/els-solutions.com\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/els.solutions\/"]},{"@type":"Person","@id":"https:\/\/els-solutions.com\/en\/#\/schema\/person\/9fb8dae537039679cfc537a000df6ca3","name":"Marketing ELS","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/els-solutions.com\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/b785df1d10c9806cc43fcea2dbf585b96a8761ff697010979d603fc5b7a9ca7b?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b785df1d10c9806cc43fcea2dbf585b96a8761ff697010979d603fc5b7a9ca7b?s=96&d=mm&r=g","caption":"Marketing ELS"},"sameAs":["https:\/\/els-solutions.com\/"]}]}},"_links":{"self":[{"href":"https:\/\/els-solutions.com\/en\/wp-json\/wp\/v2\/posts\/7601","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/els-solutions.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/els-solutions.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/els-solutions.com\/en\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/els-solutions.com\/en\/wp-json\/wp\/v2\/comments?post=7601"}],"version-history":[{"count":1,"href":"https:\/\/els-solutions.com\/en\/wp-json\/wp\/v2\/posts\/7601\/revisions"}],"predecessor-version":[{"id":7602,"href":"https:\/\/els-solutions.com\/en\/wp-json\/wp\/v2\/posts\/7601\/revisions\/7602"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/els-solutions.com\/en\/wp-json\/wp\/v2\/media\/7591"}],"wp:attachment":[{"href":"https:\/\/els-solutions.com\/en\/wp-json\/wp\/v2\/media?parent=7601"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/els-solutions.com\/en\/wp-json\/wp\/v2\/categories?post=7601"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/els-solutions.com\/en\/wp-json\/wp\/v2\/tags?post=7601"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}